WHAT IS CLAIMED IS:

1. A compound of the formula I:



W is selected from the group consisting of:
C, N, and -O-, wherein when W is N, then R^4 is absent, and when W is -O-, then both R^3 and R^4 are absent;

X is selected from the group consisting of:
$-NR^{10}-$, -O-, $-CH_2O-$, $-CONR^{10}-$, $-NR^{10}CO-$, $-CO_2-$, -OCO-,
$-CH_2(NR^{10})CO-$, $-N(COR^{10})-$, and $-CH_2N(COR^{10})-$,
and where R^{10} is independently selected from: hydrogen, C_{1-6} alkyl, benzyl, phenyl, and C_{1-6} alkyl-C_{3-6} cycloalkyl,
which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, C_{1-3}alkyl, C_{1-3}alkoxy and trifluoromethyl;
or where R^{10} and R^2 may be joined together to form a 5- or 6-membered ring,

R^1 is selected from:
hydrogen, $-C_{0-6}$alkyl-Y-phenyl-, $-C_{0-6}$alkyl-Y-heterocycle-,
$-C_{0-6}$alkyl-Y-(C_{1-6}alkyl)-, and
$-(C_{0-6}$alkyl)-Y-(C_{0-6}alkyl)-(C_{3-7}cycloalkyl)-(C_{0-6}alkyl),
where Y is selected from:
a single bond, -O-, -S-, -SO-, $-SO_2-$, and $-NR^{10}-$,
and where the phenyl, heterocycle, alkyl and the cycloalkyl are unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:
(a) halo,

(b) hydroxy,
(c) -O-C_{1-3}alkyl,
(d) trifluoromethyl,
(e) C_{1-3}alkyl,
(f) -C_{3-6}cycloalkyl
(g) -CO_2R^9, wherein R^9 is independently selected from: hydrogen, C_{1-6} alkyl, C_{5-6} cycloalkyl, benzyl or phenyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, C_{1-3}alkyl, C_{1-3}alkoxy and trifluoromethyl,
(h) -CN,
(i) -NR^9R^{10},
(j) -NR^9COR^{10},
(k) -$NR^9SO_2R^{10}$,
(l) -$NR^9CO_2R^{10}$,
(m) -$NR^9CONR^9R^{10}$,
(n) -$CONR^9R^{10}$,
(o) heterocycle,
(p) phenyl;

R^2 is selected from:
(C_{0-6}alkyl)-phenyl and (C_{0-6}alkyl)-heterocycle,
where the alkyl is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:
(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl,
(d) trifluoromethyl,
(e) -C_{1-3}alkyl,
(f) -CO_2R^9, and
(g) oxo;
and where the phenyl and the heterocycle may be unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
(a) halo,
(b) trifluoromethyl,

(c) trifluoromethoxy,
(d) hydroxy,
(e) C_{1-6}alkyl,
(f) C_{3-7}cycloalkyl,
(g) -O-C_{1-6}alkyl,
(h) -O-C_{3-7}cycloalkyl,
(i) -SCF_3,
(j) -S-C_{1-6}alkyl,
(k) -SO_2-C_{1-6}alkyl,
(l) phenyl,
(m) heterocycle,
(n) -CO_2R^9,
(o) -CN,
(p) -NR^9R^{10},
(q) -NR^9-SO_2-R^{10},
(r) -SO_2-NR^9R^{10},
(s) -$CONR^9R^{10}$, and
(t) -O-phenyl;

R^3 is selected from:
hydrogen, (C_{0-6}alkyl)-phenyl, (C_{0-6}alkyl)-heterocycle, C_{1-6}alkyl, CF_3, C_{3-7}cycloalkyl, -NR^9R^{10}, -CO_2R^9, -NR^9-SO_2-R^{10}, -$NR^9CONR^9R^{10}$, and –$CONR^9R^{10}$,
where the alkyl is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl, and
(d) trifluoromethyl,
and where the phenyl, heterocycle, and cycloalkyl are unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
(a) halo,
(b) trifluoromethyl,
(c) hydroxy,
(d) C_{1-3}alkyl,

(e) -O-C_{1-3}alkyl,
(f) -CO_2R^9,
(g) -CN,
(h) -NR^9R^{10}, and
(i) -$CONR^9R^{10}$
(j) $NR^9SO_2R^{10}$,
(k) $SO_2NR^9R^{10}$
(l) phenyl,
(m) heterocycle;

and where the phenyl, heterocycle, and cycloalkyl may or may not be fused to another phenyl or heterocycle;

R^4 is selected from:

(a) hydrogen,
(b) hydroxy,
(c) C_{1-6}alkyl,
(d) C_{1-6}alkyl-hydroxy,
(e) -O-C_{1-3}alkyl,
(f) $C_{0-6}CO_2R^9$,
(g) -$CONR^9R^{10}$, and
(h) -CN;

or R^3 and R^4 may be joined together to form a ring which is selected from:

(a) 1H-indene,
(b) 2,3-dihydro-1H-indene,
(c) 2,3-dihydro-benzofuran,
(d) 1,3-dihydro-isobenzofuran,
(e) 2,3-dihydro-benzothiofuran, and
(f) 1,3-dihydro-isobenzothiofuran,

where the 1H-indene, 2,3-dihydro-1H-indene, 2,3-dihydro-benzofuran, 1,3-dihydro-isobenzofuran, 2,3-dihydro-benzothiofuran, and 1,3-dihydro-isobenzothiofuran may be unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(i) halo,
(ii) trifluoromethyl,

(iii) hydroxy,
(iv) C_{1-3}alkyl,
(v) -O-C_{1-3}alkyl,
(vi) $C_{0-4}CO_2R^9$,
(vii) -CN,
(viii) $-NR^9R^{10}$, and
(ix) $-CONR^9R^{10}$
(x) $NR^9SO_2R^{10}$,
(xi) $SO_2NR^9R^{10}$
(xii) phenyl,
(xiii) heterocycle;

R^5, R^6, R^7 and R^8 are independently selected from:

(a) hydrogen,
(b) hydroxy,
(c) C_{1-6}alkyl,
(d) C_{1-6}alkyl-hydroxy,
(e) -O-C_{1-3}alkyl,
(f) oxo, and
(g) halo,
(h) $C_{0-4}CO_2R^9$, and
(i) CF_3,

or where R^5 and R^6, or R^7 and R^8 may be joined together via a C_{2-3}alkyl chain to form a ring, or where R^3 and R^5, or R^4 and R^6 may be joined together to form a ring which is phenyl, heterocycle, or cycloalkyl, wherein the ring is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

(i) halo,
(ii) trifluoromethyl,
(iii) hydroxy,
(iv) C_{1-3}alkyl,
(v) -O-C_{1-3}alkyl,
(vi) $-CO_2R^9$,
(vii) -CN,

(viii) $-NR^9R^{10}$,
(ix) $-CONR^9R^{10}$, and
(x) phenyl;

R^{11} is selected from:

(a) hydrogen,
(b) halo
(c) C_{1-6}alkyl,
(d) hydroxy,
(e) CO_2R^9,
(f) $-O-C_{1-3}$alkyl, and
(g) $-NR^9R^{10}$;

R^{12} is selected from:

(a) hydrogen,
(b) C_{1-6}alkyl, and
(c) CO_2R^9;

n is an integer selected from 0, 1, 2 and 3;

and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

2. The compound of Claim 1 of the formula Ib:



Ib

wherein the dashed line represents a single or a double bond and wherein R^{15} and R^{16} are independently selected from:

(a) hydrogen,
(b) halo,
(c) trifluoromethyl,
(d) hydroxy,
(e) C_{1-3}alkyl,
(f) -O-C_{1-3}alkyl,
(g) -CO_2H,
(h) -CO_2C_{1-3}alkyl,
(i) -CN, and
(j) heterocycle;

and pharmaceutically acceptable salts and individual diastereomers thereof.

3. The compound of Claim 1 of the formula Ic:



Ic

and pharmaceutically acceptable salts and individual isomers thereof.

4. The compound of Claim 1 of the formula Id:



Id

where Z is a heterocycle selected from the group consisting of:

benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof, and where the heterocycle may be unsubstituted or substituted with 1-3 substituents, where the substituents are selected from:

(a) hydrogen,
(b) halo,
(c) trifluoromethyl,
(d) hydroxy,
(e) C_{1-3}alkyl,
(f) -O-C_{1-3}alkyl,
(g) $-CO_2H$,
(h) $-CO_2C_{1-3}$alkyl, and
(i) -CN,

and where the heterocycle may be fused to a phenyl or another heterocycle, and pharmaceutically acceptable salts and individual diastereomers thereof.

5. The compound of Claim 1 wherein X is -CONH-.

6. The compound of Claim 1 wherein R^1 is selected from: -C_{0-6}alkyl-phenyl, C_{0-6}alkyl-heterocycle, -C_{1-6}alkyl, -C_{0-6}alkyl-O-C_{1-6}alkyl-, -C_{0-6}alkyl-S-C_{1-6}alkyl-, and -(C_{0-6}alkyl)-(C_{3-7}cycloalkyl)-(C_{0-6}alkyl),

where the phenyl, heterocycle, alkyl and the cycloalkyl are unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl,
(d) trifluoromethyl,
(e) C_{1-3}alkyl,
(f) -C_{3-6}cycloalkyl
(g) -CO_2R^9, wherein R^9 is independently selected from: hydrogen, C_{1-6} alkyl, C_{5-6} cycloalkyl, benzyl or phenyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, C_{1-3}alkyl, C_{1-3}alkoxy and trifluoromethyl,
(h) -CN,
(i) -NR^9R^{10},
(j) -NR^9COR^{10},
(k) -$NR^9SO_2R^{10}$,
(l) -$NR^9CO_2R^{10}$,
(m) -$NR^9CONR^9R^{10}$,
(n) -$CONR^9R^{10}$, and
(p) phenyl.

7. The compound of Claim 6 wherein R^1 is selected from:

(1) -C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 substituents where the substituents are independently selected from:
(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl,
(d) trifluoromethyl,
(e) -CN,
(f) -$NR^9SO_2R^{10}$,
(g) -$NR^9CO_2R^{10}$,
(h) -$NR^9CONR^9R^{10}$,
(i) heterocycle,

(j) $-CO_2R^9$, and
(k) $-CONR^9R^{10}$,

(2) $-C_{0-6}$alkyl-O-C_{1-6}alkyl-, which is unsubstituted or substituted with 1-6 substituents where the substituents are independently selected from:
(a) halo, and
(b) trifluoromethyl,

(3) $-C_{0-6}$alkyl-S-C_{1-6}alkyl-, which is unsubstituted or substituted with 1-6 substituents where the substituents are independently selected from:
(a) halo, and
(b) trifluoromethyl,

(4) -(C_{3-5}cycloalkyl)-(C_{0-6}alkyl), which is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:
(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl,
(d) trifluoromethyl,
(e) -CN,
(f) $-NR^9SO_2R^{10}$,
(g) $-NR^9CO_2R^{10}$,
(h) $-NR^9CONR^9R^{10}$,
(i) heterocycle,
(j) $-CO_2R^9$, and
(k) $-CONR^9R^{10}$,

(5) phenyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl,
(d) trifluoromethyl,
(e) -CN,
(f) $-NR^9SO_2R^{10}$,
(g) $-NR^9CO_2R^{10}$,
(h) $-NR^9CONR^9R^{10}$,
(i) heterocycle,

(j) $-CO_2R^9$, and
(k) $-CONR^9R^{10}$,

or where the phenyl may be fused to another phenyl or heterocycle,

(6) heterocycle, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(a) halo,
(b) hydroxy,
(c) $-O-C_{1-3}$alkyl,
(d) trifluoromethyl,
(e) -CN,
(f) $-NR^9SO_2R^{10}$,
(g) $-NR^9CO_2R^{10}$,
(h) $-NR^9CONR^9R^{10}$,
(i) heterocycle,
(j) $-CO_2R^9$, and
(k) $-CONR^9R^{10}$,

or where the heterocycle may be fused to another heterocycle or a phenyl.

8. The compound of Claim 7 wherein that R^1 is selected from:

(1) $-CH(CH_3)_2$,
(2) $-CH_2CH_2CH_3$,
(3) $-CH_2CH(CH_3)_2$,
(4) -cyclopropyl,
(5) -cyclobutyl,
(6) -cyclopentyl,
(7) $-CH_2$-cyclopropyl,
(8) $-CH_2$-cyclobutyl,
(9) $-C(CH_3)_2(OH)$,
(10) -(OH)cyclobutyl,
(11) -(OH)cyclopentyl,
(12) $-C(CH_3)_2(NHCOCH_3)$,
(13) $-O-CH_3$,
(14) $-O-CH(CH_3)_2$,
(15) $-S-CH_3$,

(16) -S-CF_3,

(17) -SO_2-CH_3,

(18) -S-$CH(CH_3)_2$,

(19) -SO_2-$CH(CH_3)_2$,

(20) -NH-SO_2-CH_3,

(21) -phenyl,

(22) 

(23) 

(24) 

(25) 

(26) 

(27) 

(28) 

(29) 

(30) 

(31) 

(32) 

(33) 

(34) 

(35) 

(36) 

(37) 

(38) 

(39) 

(40) 

(41) 

(42) 

(43) 

(44) 

(45) 

(46) 

(47) 

(48) 

(49) 

(50) 

(51) 

(52) 

(53) 

(54) 

and positional and stereo isomers thereof.

9. The compound of Claim 1 wherein R^2 is selected from:
-(C_{0-4}alkyl)-phenyl and -(C_{0-4}alkyl)-heterocycle,
where heterocycle is selected from:
furanyl, imidazolyl, oxadiazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyridazinyl, pyrimidyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and triazolyl, and N-oxides thereof,
where the alkyl is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:
(a) halo,

(b) hydroxy,
(c) -O-C_{1-3}alkyl,
(d) trifluoromethyl,
(e) -CO_2R^9

and where the phenyl or heterocycle is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) trifluoromethoxy,
(d) hydroxy,
(e) C_{1-3}alkyl,
(f) -O-C_{1-3}alkyl,
(g) -CO_2R^9,
(h) -S-C_{1-3}alkyl,
(i) -SO_2-C_{1-3}alkyl,
(j) -SCF_3,
(k) -OPh,
(l) -NR^9R^{10},
(m) -NR^9-SO_2-R^{10},
(n) -SO_2-NR^9R^{10},
(o) -$CONR^9R^{10}$, and
(p) heterocycle.

10. The compound of Claim 9 wherein

R^2 is selected from:

-CH_2-phenyl and -CH_2-heterocycle, where the heterocycle is selected from: pyridyl, pyridazinyl, pyrimidyl, and N-oxides thereof,

and where the phenyl or heterocycle is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) trifluoromethoxy,
(d) hydroxy,
(e) C_{1-3}alkyl,

(f) -O-C_{1-3}alkyl,
(g) -CO_2-C_{1-3}alkyl,
(h) -CO_2H,
(i) -S-C_{1-3}alkyl,
(j) -SO_2-C_{1-3}alkyl,
(k) -SCF_3,
(l) -NH_2,
(m) -NH-SO_2-C_{1-3}alkyl,
(n) -SO_2-NH_2, and
(o) heterocycle.

11. The compound of Claim 10 wherein R^2 is selected from:
(1) -CH_2-(phenyl),
(2) -CH_2-(4-bromophenyl),
(3) -CH_2-(3-chlorophenyl),
(4) -CH_2-(3,5-difluorophenyl),
(5) -CH_2-((2-trifluoromethyl)phenyl),
(6) -CH_2-((3-trifluoromethyl)phenyl),
(7) -CH_2-((4-trifluoromethyl)phenyl),
(8) -CH_2-((3-trifluoromethoxy)phenyl),
(9) -CH_2-((3-trifluoromethylthio)phenyl),
(10) -CH_2-((3-trifluoromethoxy-5-thiomethyl)phenyl),
(11) -CH_2-((3-trifluoromethoxy-5-methoxy)phenyl),
(12) -CH_2-((3-trifluoromethoxy-5-methanesulfonyl)phenyl),
(13) -CH_2-((3-trifluoromethoxy-5-amino)phenyl),
(14) -CH_2-((3-trifluoromethoxy-5-aminomethanesulfonyl)phenyl),
(15) -CH_2-((3-trifluoromethoxy-5-sulfonylamino)phenyl),
(16) -CH_2-((3,5-bis-trifluoromethyl)phenyl),
(17) -CH_2-((3-fluoro-5-trifluoromethyl)phenyl),
(18) -$CH(CH_3)$-((3,5-bis-trifluoromethyl)phenyl),
(19) -$C(CH_3)_2$-((3,5-bis-trifluoromethyl)phenyl),
(20) -CH_2-(4-(2-trifluoromethyl)pyridyl),
(21) -CH_2-(5-(3-trifluoromethyl)pyridyl),
(22) -CH_2-(5-(3-trifluoromethyl)pyridazinyl),

(23) -CH_2-(4-(2-trifluoromethyl)pyridyl-N-oxide), and

(24) -CH_2-(5-(3-trifluoromethyl)pyridyl-N-oxide).

12. The compound of Claim 1 wherein R^3 is phenyl or heterocycle, where the phenyl or heterocycle is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(a) halo,

(b) trifluoromethyl,

(c) hydroxy,

(d) C_{1-3}alkyl,

(e) -O-C_{1-3}alkyl,

(f) -CO_2R^9,

(g) -CN,

(h) -NR^9R^{10}, and

(i) -$CONR^9R^{10}$.

13. The compound of Claim 12 wherein R^3 is phenyl or heterocycle, where the phenyl or heterocycle is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from:

(a) halo,

(c) hydroxy,

(d) C_{1-3}alkyl,

(e) -O-C_{1-3}alkyl, and

(f) -CO_2R^9.

14. The compound of Claim 13 wherein R^3 isphenyl, para-fluorophenyl, 3-carboxyphenyl, 3-pyridyl, 3,5-pyrimidyl, 1-benzimidazole, 3-indole, 1-indazole, 1-pyrrole, imidazoyl, diazoyl, triazoyl or tetrazoyl.

15. The compound of Claim 1 wherein R^4 is selected from:

(a) hydrogen,

(b) hydroxy,

(c) -CO_2C_{1-6}alkyl,
(d) -CN,
(e) fluoro, and
(f) methyl.

16. The compound of Claim 1 wherein
R^5 and R^6 are independently selected from:
(a) hydrogen,
(b) hydroxy,
(c) -CH_3,
(d) -O-CH_3,
(e) oxo, and
(f) -fluoro.

17. The compound of Claim 1 wherein R^{11} is hydrogen.

18. The compound of Claim 1 wherein R^{12} is hydrogen.

19. The compound of Claim 1 of the formula:



wherein the dashed line represents a single or a double bond,
R^5 is hydrogen or methyl;
and pharmaceutically acceptable salts and individual diastereomers thereof.

20. The compound of Claim 1 of the formula:



and pharmaceutically acceptable salts and individual diastereomers thereof.

21. The compound of Claim 1 of the formula:

















and pharmaceutically acceptable salts and individual diastereomers thereof.

22. A compound which is selected from the group consisting of the title compounds of the Examples, and pharmaceutically acceptable salts and individual diastereomers thereof.

23. A pharmaceutical composition which comprises an inert carrier and a compound of Claim 1.

24. A method for modulation of chemokine receptor activity in a mammal in need thereof which comprises the administration of an effective amount of the compound of Claim 1.

25. A method for treating, ameliorating or controlling an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim 1.

26. A method for reducing the risk of an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim 1.

27. A method for treating, ameliorating or controlling rheumatoid arthritis which comprises administering to a patient in need thereof an effective amount of the compound of Claim 1.